SCHEMBL9924286

SCHEMBL9924286

O=C1CCC(N/C(=N\C(=O)c2ccc(C(F)(F)F)cc2)Nc2cc(F)cc(Cl)c2)CC1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LHCGR P22888 1/20 0.39
RAPGEF3 O95398 2/20 0.38
RAPGEF4 Q8WZA2 2/20 0.38
GRM4 Q14833 1/20 0.37
CYP2D6 P10635 1/20 0.37
MC5R P33032 1/20 0.36
EPHX2 P34913 2/20 0.35
ALDH1A1 P00352 1/20 0.35
EPAS1 Q99814 1/20 0.35
SLC6A9 P48067 3/20 0.35
RHOC P08134 2/20 0.35
RHOA P61586 2/20 0.35
SLC6A5 Q9Y345 1/20 0.35
MAPT P10636 1/20 0.35
CCR3 P51677 2/20 0.35
CRHR1 P34998 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9924261 0.90 TRPV1 (0.42) LHCGRRAPGEF3RAPGEF4GRM4CYP2D6
SCHEMBL17206704 0.84 CYP2D6 (0.37) LHCGRRAPGEF3RAPGEF4CYP2D6EPHX2
SCHEMBL9924081 0.82 TRPV1 (0.44) RAPGEF3RAPGEF4GRM4CYP2D6SLC6A9
SCHEMBL9924438 0.82 TRPV1 (0.44) RAPGEF3RAPGEF4GRM4CYP2D6SLC6A9
SCHEMBL9924215 0.80 SLC6A9 (0.41) GRM4CYP2D6MC5REPHX2ALDH1A1
SCHEMBL9924333 0.79 NPC1 (0.44) GRM4MC5RCCR3CRHR1
SCHEMBL9924083 0.79 NPC1 (0.44) GRM4MC5RCCR3CRHR1
SCHEMBL17206736 0.78 GRM4 (0.38) LHCGRRAPGEF3RAPGEF4GRM4CYP2D6
SCHEMBL9924090 0.78 APOB (0.40) RAPGEF3RAPGEF4GRM4MC5REPHX2
SCHEMBL9924450 0.77 NPC1 (0.47) GRM4MC5REPHX2ALDH1A1SLC6A9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169199-B2 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-10-27 US disclosed
US-9169199-B2 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-10-27 US disclosed
WO-2012078867-A2 CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION (US) 2012-06-14 WO disclosed